SCHEMBL5570650

SCHEMBL5570650

COc1cc(C=CC=CC(=O)N2CCN(CCN3CCN(C(=O)C=CC=Cc4cc(OC)c(OC)c(OC)c4)CC3)CC2)cc(OC)c1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.63
ALDH1A1 P00352 7/20 0.63
HPGD P15428 5/20 0.63
CYP3A4 P08684 1/20 0.53
CYP2C19 P33261 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
ATM Q13315 1/20 0.52
ABCB1 P08183 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.50
HSD17B10 Q99714 2/20 0.48
GAA P10253 1/20 0.48
HTT P42858 1/20 0.48
HTR1A P08908 1/20 0.48
HTR2C P28335 1/20 0.48
TP53 P04637 2/20 0.47
STAT6 P42226 1/20 0.47
MAPT P10636 1/20 0.47
SLC29A1 Q99808 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5570647 1.00 KDM4E (0.63) KDM4EALDH1A1HPGDCYP3A4CYP2C19
Hydrochloric Acid SCHEMBL5572592 0.99 KDM4E (0.62) KDM4EALDH1A1HPGDCYP3A4CYP2C19
Hydrochloric Acid SCHEMBL5572589 0.99 KDM4E (0.62) KDM4EALDH1A1HPGDCYP3A4CYP2C19
SCHEMBL5574112 0.95 KDM4E (0.60) KDM4EALDH1A1HPGDCYP3A4CYP2C19
SCHEMBL5574117 0.95 KDM4E (0.60) KDM4EALDH1A1HPGDCYP3A4CYP2C19
Hydrochloric Acid SCHEMBL5570632 0.94 KDM4E (0.59) KDM4EALDH1A1HPGDCYP3A4CYP2C19
Hydrochloric Acid SCHEMBL5570637 0.94 KDM4E (0.59) KDM4EALDH1A1HPGDCYP3A4CYP2C19
SCHEMBL6785121 0.92 ALDH1A1 (0.72) KDM4EALDH1A1HPGDCYP3A4CYP2C19
SCHEMBL5570655 0.90 KDM4E (0.61) KDM4EALDH1A1HPGDCYP3A4CYP2C19
SCHEMBL5570660 0.90 KDM4E (0.61) KDM4EALDH1A1HPGDCYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1057815-B1 CYCLIC AMIDE COMPOUNDS KOWA CO (JP) 2007-09-05 EP disclosed
US-6645957-B2 Useful in preventing and treating allergic immunological diseases; treating asthma, atopic dermatitis, allergic rhinitis, inflammatory large bowel disease, contact dermatitis KOWA CO., LTD. (JP) 2003-11-11 US disclosed
US-20030096828-A1 Cyclic amide compound KOWA CO., LTD. (JP) 2003-05-22 US disclosed
US-6448242-B1 COMPOUND HAVING A STRONG INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY; ANTIALLERGENS KOWA CO., LTD. (JP) 2002-09-10 US disclosed
EP-1057815-A1 CYCLIC AMIDE COMPOUNDS Kowa Co., Ltd. (JP) 2000-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096828-A1 Cyclic amide compound CMA1, HRH2, HRH4 KDM4E 218/4885ALDH1A1 2028/4885HPGD 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.